Behnam Tehrani, MD
Cardiovascular Disease · Falls Church, VANPI 1639338551
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abiomed at 48.1% of the total. Reporting peaked in 2019 at $36,136 and has fallen 56.8% since, to $15,594 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $321.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$28K
- Medtronic$18K
- Recor Medical Inc$6K
- Abbott$2K
- Getinge USA Sales, LLC$2K
- Boston Scientific$1K
- plus $2K from 15 others
Across 222 payments — averaging $2052.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$238K
- Procyrion, Inc.$85K
- Boston Scientific$68K
- Cathworks, Inc.$64K
- Abiomed$142
What the payments were for
- Consulting fees$6,55011%
- Speaking & faculty fees$30,34452%
- Travel & lodging$13,63723%
- Food & beverage$7,60713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 44 | $27,967 |
| Medtronic(2 entities) | 34 | $17,523 |
| Recor Medical Inc | 24 | $6,170 |
| Abbott | 8 | $1,651 |
| Getinge USA Sales, LLC | 2 | $1,517 |
| Boston Scientific | 18 | $1,418 |
| Inari Medical, Inc. | 3 | $528 |
| Cardiovascular Systems Inc. | 25 | $378 |
| Shockwave Medical, Inc | 4 | $292 |
| Edwards Lifesciences | 2 | $163 |
| Teleflex LLC | 2 | $106 |
| Philips North America LLC | 3 | $104 |
| Angiodynamics, Inc. | 1 | $83 |
| Amgen | 3 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| AstraZeneca | 1 | $30 |
| GSK | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Procyrion, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$27,290
- Resolute$8,094
- Paradise Ultrasound Renal Denervation System$5,953
- FFRangio$3,758
- HeartMate Touch$1,050
- CARDIOSAVE HYBRID, TYPE B PLUG$1,000
- Vasoview Hemopro 2$517
- SYMPLICITY G3$424
- FLOWTRIEVER CATHETER, S$420
- GENERAL - THERAPIES$264
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$253
- FlowTriever$243
- ClotTriever$243
- CardioMEMS HF System$160
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$158
- CT THROMBECTOMY SYSTEM KIT$151
- MitraClip$148
- WATCHMAN Access System$132
- Diamondback Coronary$130
- AVVIGO Guidance System$129
How this compares
$58,138 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $183,277 |
| EntrestoSacubitril/Valsartan | 49 | $79,462 |
| Repatha SureclickEvolocumab | 44 | $54,159 |
| JardianceEmpagliflozin | 24 | $37,393 |
| XareltoRivaroxaban | 29 | $34,598 |
| VascepaIcosapent Ethyl | 29 | $10,653 |
| Rosuvastatin Calcium | 499 | $8,674 |
| Ranolazine ErRanolazine | 30 | $3,729 |
| Metoprolol Succinate | 243 | $3,561 |
| Losartan Potassium | 181 | $1,942 |
| Ezetimibe | 54 | $1,786 |
| Atorvastatin Calcium | 154 | $1,751 |
| ClopidogrelClopidogrel Bisulfate | 122 | $1,566 |
| Amlodipine Besylate | 176 | $1,402 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 69 | $1,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $20 | $34,59829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Falls Church
- Alexander TruesdellFalls Church$167K
- Christopher OconnorFalls Church$161K
- Joseph KreppFalls Church$74K
- Mitchell PsotkaFalls Church$35K
- Tariq HaddadFalls Church$18K
- Leonard IlkhanoffFalls Church$14K
- Shashank SinhaFalls Church$12K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.